The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Antonov V.N.

Federal State Budgetary Educational Institution of Higher Education “South Ural State Medical University” of the Ministry of Health of the Russian Federation

Ignatova G.L.

Federal State Budgetary Educational Institution of Higher Education “South Ural State Medical University” of the Ministry of Health of the Russian Federation

Blinova E.V.

Federal State Budgetary Educational Institution of Higher Education “South Ural State Medical University” of the Ministry of Health of the Russian Federation

Grebneva I.V.

Federal State Budgetary Educational Institution of Higher Education “South Ural State Medical University” of the Ministry of Health of the Russian Federation

Rodionova O.V.

State Autonomous Healthcare Institution “Regional Clinical Hospital No. 3”

Domashenko M.A.

Central Clinical Medical and Sanitary Unit

Reserves for reducing exacerbations in patients with chronic obstructive pulmonary disease at a large industrial enterprise

Authors:

Antonov V.N., Ignatova G.L., Blinova E.V., Grebneva I.V., Rodionova O.V., Domashenko M.A.

More about the authors

Journal: Journal of Respiratory Medicine. 2025;1(2): 66‑70

Read: 591 times


To cite this article:

Antonov VN, Ignatova GL, Blinova EV, Grebneva IV, Rodionova OV, Domashenko MA. Reserves for reducing exacerbations in patients with chronic obstructive pulmonary disease at a large industrial enterprise. Journal of Respiratory Medicine. 2025;1(2):66‑70. (In Russ.)
https://doi.org/10.17116/respmed2025102166

Recommended articles:

References:

  1. Clinical guidelines of the Ministry of Health of Russia «Chronic obstructive pulmonary disease», 2024. Accessed April 14,2025. (In Russ.). https://cr.minzdrav.gov.ru/view-cr/603_3
  2. González Del Castillo J, Candel FJ, de la Fuente J, Gordo F, Martín-Sánchez FJ, Menéndez R, Mujal A, Barberán J. Manejo integral del paciente con exacerbación aguda de la enfermedad pulmonar Integral approach to the acute exacerbation of chronic obstructive pulmonary disease. Rev Esp Quimioter. 2018 Oct;31(5):461-484. (Spanish).
  3. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2025 report. Electronic resource. Accessed April 14,2025. https://goldcopd.org/2025-gold-report/
  4. Guía de Práctica Clínica para el Diagnóstico y Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) ‒ Guía Española de la EPOC (GesEPOC). Archivos de Bronconeumología. 2012;48(1):2-58.  https://doi.org/10.1016/S0300-2896(12)70035-2
  5. Singh D, Han MK, Hawkins NM, Hurst JR, Kocks JWH, Skolnik N, Stolz D, El Khoury J, Gale CP. Implications of Cardiopulmonary Risk for the Management of COPD: A Narrative Review. Adv Ther. 2024 Jun;41(6):2151-2167. https://doi.org/10.1007/s12325-024-02855-4
  6. Vidigal MTC, Borges GH, Rabelo DH, de Andrade Vieira W, Nascimento GG, Lima RR, Costa MM, Herval ÁM, Paranhos LR. Cost-effectiveness of home care compared to hospital care in patients with chronic obstructive pulmonary disease (COPD): a systematic review. Front Med (Lausanne). 2024;11:1405840. https://doi.org/10.3389/fmed.2024.1405840
  7. Rehman AU, Hassali MAA, Muhammad SA, Harun SN, Shah S, Abbas S. The economic burden of Chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature. Eur J Health Econ. 2020;21(2):181-194.  https://doi.org/10.1007/s10198-019-01119-1
  8. Patel JG, Coutinho AD, Lunacsek OE, Dalal AA. COPD affects worker productivity and health care costs. Int J Chron Obstruct Pulmon Dis. 2018;13:2301-2311. https://doi.org/10.2147/COPD.S163795
  9. GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2100-2132. https://doi.org/10.1016/S0140-6736(24)00367-2
  10. Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I; NIHR RESPIRE Global Respiratory Health Unit. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022 May;10(5):447-458.  https://doi.org/10.1016/S2213-2600(21)00511-7
  11. Andreeva E, Pokhaznikova M, Lebedev A, Moiseeva I, Kutznetsova O, Degryse JM. The prevalence of chronic obstructive pulmonary disease by the Global Lung Initiative equations in North-Western Russia. Respiration. 2016;91(1):43-55.  https://doi.org/10.1159/000442887
  12. Drapkina OM, Kontsevaya AV, Mukaneeva DK, Smirnova MI, Antsiferova AA, Lukyanov MM, Myrzamatova AO, Mokhovikov GI, Khudyakov MB, Avdeev SN. Forecast of the socioeconomic burden of COPD in the Russian Federation in 2022. Pulmonologiya. 2022;32(4):507-516. (In Russ.). https://doi.org/10.18093/0869-0189-2022-32-4-507-516
  13. Avdeev SN, Nikitina LYu, Merzhoeva ZM, Nuralieva GS, Gainitdinova VV, Dzhioeva ON, Shamshurina NG, Berikkhanov ZG, Kharlamova SA, Deev IA, Krokhin KA. Reality and prospects of the pulmonological care for patients with chronic obstructive pulmonary disease in the Russian Federation. RMJ. 2024;1:2-6. (In Russ.).
  14. DeWeerdt S, Grouse L. Chronic Airways Diseases: A Guide for Primary Care Physicians. 2005.
  15. Milačić N, Milačić B, Dunjić O, Milojković M. Validity of CAT and mMRC — dyspnea score in evaluation of COPD severity. Acta Medica Medianae. 2015;54(1):66-70.  https://doi.org/10.5633/amm.2015.0111
  16. Gruffydd-Jones K, Marsden HC, Holmes S, Kardos P, Escamilla R, Dal Negro R, Roberts J, Nadeau G, Vasselle M, Leather DA, Jones P. Utility of COPD Assessment Test (CAT) in primary care consultations: a randomised controlled trial. Prim Care Respir J. 2013;22(1):37-43.  https://doi.org/10.4104/pcrj.2013.00001
  17. Avdeev SN, Trushenko NV. Triple therapy in chronic obstructive pulmonary disease. Pulmonologiya. 2019;29(2):199-206. (In Russ.). https://doi.org/10.18093/0869-0189-2019-29-2-199-206
  18. Muro S, Seki M, Hurst JR, Petullo D, Marshall J, Bowen K, Darken PF, Duncan EA, Megally A, Patel M. Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS. Int J Chron Obstruct Pulmon Dis. 2024;19:2729-2737. https://doi.org/10.2147/COPD.S478349

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.